

1 20. The method according to claim 19, wherein the 9-nitro-20(S)-camptothecin and 5-
2 fluoruracil are delivered in combination.

1 21. The method according to claim 19, wherein the disease associated with undesirable or
uncontrolled cell proliferation is cancer.

1 22. The method according to claim 19, wherein the cancer is selected from the group
2 consisting of acute myelogenous leukemia, cholangiocarcinoma, chronic myelogenous
3 leukemia, lymphoma, melanoma, multiple myeloma, osteosarcoma, gastric sarcoma, glioma,
4 bladder, breast, cervical, colorectal, lung, ovarian, pancreatic, prostate, and stomach cancer.

1 23. The method according to claim 19, wherein the disease associated with undesirable or
2 uncontrolled cell proliferation is restenosis. —

REMARKS

Consideration is respectfully requested in view of the above amendments. Applicants earnestly believe that they are entitled to a letters patent, and respectfully solicit the Examiner to expedite prosecution of this patent application to issuance. Should the Examiner have any questions, the Examiner is encouraged to telephone the undersigned.

Respectfully submitted,

Date: Feb 11, 2002

By: David J. Weitz
David J. Weitz
Registration No. 38,362

WILSON SONSINI GOODRICH & ROSATI
650 Page Mill Road
Palo Alto, CA 94304-1050
(650) 493-9300

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Title:

[COMBINATION THERAPY INCLUDING CAMPTOTHECIN]
COMBINATION THERAPY INCLUDING 9-NITRO-20(S)-CAMPTOTHECIN
AND 5-FLUOROURACIL

In the Abstract:

[A method for treating diseases comprises delivering to a patient in need of treatment a therapeutically effective amount of 20(S)-camptothecin, an analog of 20(S)-camptothecin, or a derivative of 20(S)-camptothecin in combination with an effective amount of at least one of an alkylating agent, epidophyllotoxin, antimetabolite, antibiotic or vinca alkaloid.]

A method for treating a patient having a disease associated with undesirable or uncontrolled cell proliferation such as cancer and restenosis is provided. The method comprises: delivering to the patient a therapeutically effective amount of 9-nitro-20(S)-camptothecin in combination with an effective amount of an antimetabolite such as 5-fluorouracil.